Decitabine

Phase 2Terminated

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Myelodysplastic Syndrome

Conditions

Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia

Trial Timeline

Mar 1, 2005 → Nov 1, 2008

NCT ID

NCT00113321

About Decitabine

Decitabine is a phase 2 stage product being developed by Eisai for Myelodysplastic Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT00113321. Target conditions include Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00538876	Phase 1	Completed	Jul 1, 2007	Dec 1, 2009	Acute Myeloid Leukemia
NCT00477386	Phase 1/2	Completed	Jul 1, 2007	Sep 1, 2013	Ovarian Cancer
NCT00398983	Phase 2/3	Completed	Aug 1, 2006	May 1, 2012	Acute Myelogenous Leukemia
NCT00349596	Phase 1	Completed	Jul 1, 2006	Oct 1, 2014	Acute Lymphocytic Leukemia
NCT00760084	Phase 2	Completed	Jul 1, 2005	Feb 1, 2008	Acute Myelogenous Leukemia
NCT00260065	Phase 2	Completed	May 1, 2005	Dec 1, 2008	Myelodysplastic Syndrome
NCT00358644	Phase 2	Completed	Mar 1, 2005	Dec 1, 2008	Acute Myeloid Leukemia
NCT00113321	Phase 2	Terminated	Mar 1, 2005	Nov 1, 2008	Myelodysplastic Syndrome

Competing Products

20 competing products in Myelodysplastic Syndrome

See all competitors

Product	Company	Stage	Hype Score
NEX-18a injection + Azacitidine Injection	Nanexa AB	Phase 1	28
JSP191	Jasper Therapeutics	Phase 1	25
Humanized anti-CD117 Monoclonal Antibody (JSP191)	Jasper Therapeutics	Phase 1	25
GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase II	GT Biopharma	Phase 1/2	33
Erlotinib Hydrochloride	Astellas Pharma	Phase 2	52
Decitabine + Decitabine + Decitabine	Eisai	Phase 2	52
Decitabine + Valproic Acid	Eisai	Phase 2	52
decitabine + decitabine	Eisai	Phase 2	52
decitabine + azacitidine	Eisai	Approved	85
decitabine + decitabine + decitabine + decitabine	Eisai	Phase 1	33
Decitabine, Arsenic Trioxide and Ascorbic Acid	Eisai	Phase 2	52
Subcutaneous Decitabine	Eisai	Phase 1	33
Decitabine	Eisai	Phase 2	52
Galunisertib + Placebo	Eli Lilly	Phase 2/3	65
DSP-7888	Sumitomo Pharma	Phase 1/2	41
TP-0184	Sumitomo Pharma	Phase 1/2	41
Decitabine	Johnson & Johnson	Phase 2	52
Epoetin alfa	Johnson & Johnson	Phase 2	52
ZARNESTRA, tipifarnib, R115777	Johnson & Johnson	Phase 2	52
Decitabine	Johnson & Johnson	Phase 2	52

Other Products from Eisai

MecobalaminApproved

MonteplaseApproved

E2020 + PlaceboApproved

Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved

DonepezilApproved